Ariad raises $300M, plots big HQ move in Cambridge; Kirk bets on Transgenomic

 @FierceBiotech: AstraZeneca kicks tires on respiratory program ditched by J&J. Story | Follow @FierceBiotech

@JohnCFierce: Cowen's Ed Nash is predicting '16 arrival of Sarepta's eteplirsen, with $263M start Question about accelerated OK. Personally I'm doubtful. | Follow @JohnCFierce

@RyanMFierce: IBM touts push into #biotech with bug-busting gel. Should we care yet? Report | Follow @RyanMFierce

> Ariad Pharmaceuticals ($ARIA) has priced a $300 million stock offering to fund the marketing of its leukemia drug ponatinib and other expenses. Item. Also, the company has signed a lease on 244,000 square feet of office and lab space in Cambridge, MA, where it is now headquartered. The lease is on space in a yeat-to-be-completed building from Alexandria Real Estate Equities. Deal

> Transgenomic is raising $8.3 million in a private placement with biotech billionaire Randal Kirk's Third Security and other investors. Release

> Seattle Genetics ($SGEN) spotlighted some early signs of safety and efficacy form a early-stage study of its antibody-drug conjugate called ASG-5ME in metastatic pancreatic ductal adenocarcinoma. Release

Medical Device News

 @FierceMedDev: Spiking costs blunt Covidien's strong sales quarter. News | Follow @FierceMedDev

 @DamianFierce: Dx company LipoScience is going public, targeting a $40M IPO as $LPDX. Report | Follow @DamianFierce

> ResMed posts 24% income jump in another big quarter. Article

> iRobot spikes on the Street after FDA OK. Story

Pharma News

@FiercePharma: Merrill Lynch high on Bayer: The company made its list of top Euro-stocks, thanks to new drugs/pipeline. More | Follow @FiercePharma

 @AlisonBFierce: Feds OK Novavax's experimental flu vaccine program. News | Follow @AlisonBFierce

> Groups lobby White House as sunshine rule lingers. Report

> Novartis faces probes on Tekturna tactics, Iran sales. News

And Finally… U.S. researchers say that patients with hepatitis C virus are almost four times as likely to have a tattoo, linking body art to the leading cause of liver cancer, Reuters reported. Article

 

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.